Association of nucleoside reverse transcriptase inhibitor use with reduced risk of Alzheimer's disease risk

Abstract

Exposure to NRTIs, a class of anti-retroviral drugs that also block inflammasome activation, was associated with a reduction in the risk of developing AD. The reduction in risk was observed in two large, diverse health insurance databases after correcting for numerous comorbidities known to be associated with AD. Other anti-HIV therapies such as non-NRTIs, protease inhibitors, and integrase strand transferase inhibitors were not associated with a reduction in the risk of developing AD. Our work provides a rationale for randomized clinical trials of inflammasome inhibitors in AD.